Executives of Mylan N.V. say they remain committed to acquiring over the counter drug manufacturer Perrigo. So far Perrigo has rejected all purchase offers.
MiBiz reports that Mylan CEO Heather Bresch said on a conference call that she believes Perrigo shareholders will see the "compelling nature of our offer."
Perrigo CEO Joseph Papa says there is a number "at some point" where company directors would consider selling. But he says the offer from Mylan "substantially undervalues" Perrigo and its potential for growth.
Mylan's most recent offer for Perrigo was $32.7-million.
